Onco Actu du 24 mai 2016

	2. Etiologie
Evidence suggesting link between cancer and light therapy for newborn jaundice is inconclusive but warrants consideration [Dana-Farber Cancer Institute] Pediatrics editorial cautions against overreacting to ambiguous findings but advises rethinking which children need phototherapy.
Well: Lawsuits Over Baby Powder Raise Questions About Cancer Risk [NY Times] “Talcum powder is an interesting case, because it’s not something that’s necessary,” said Dr. Anne McTiernan, an epidemiologist with the Fred Hutchinson Cancer Research Center in Seattle. “If there’s any doubt, why should anyone use it?”
	3.1 Tabac
CHAMPIX® (varenicline) European Union Label Updated to Include New Safety and Efficacy Data from the EAGLES Clinical Trial Following Endorsement from CHMP [Pfizer] Black triangle indicating additional safety monitoring requirement for CHAMPIX in the EU has been removed.
Europe lifts warning on Pfizer smoking cessation drug [Reuters] European regulators have lifted a warning on Pfizer's smoking cessation drug Champix - called Chantix in the United States - after a clinical study concluded it did not appear to increase the risk of neuropsychiatric side effects.
	3.1.1 Tabac - e-cigs
U.S. e-cigarette use stalls as health concerns grow: Reuters/Ipsos poll [Reuters] About 10 percent of the 9,766 adults surveyed between April 19 and May 16 use the devices, the same percentage as in a similar Reuters/Ipsos poll in May, 2015. This year, however, a growing percentage of participants expressed negative attitudes toward e-cigarettes.
	3.3 Prévention - Vaccins
Raging Bullsh*t, part 3: Robert De Niro says he’s teaming up with Harvey Weinstein to make an antivaccine movie [Respectful Insolence] It’s the continuation of a process that, depressingly, revealed Robert De Niro to be perhaps the biggest A-list antivaccine celebrity out there.
	4.1 Dép., diag. & prono. - Prostate
New hope for prostate cancer screening [The Institute of Cancer Research] The researchers took prostate biopsies from 100 men aged 40–69 years who had a family history of prostate cancer. They found that one quarter of the men had tumours — nearly half of these were a more aggressive form of the disease, known as non-indolent prostate cancer, that required immediate treatment.
	4.12 Biopsies liquides
Liquid biopsy – liquid gold for cancer management? [PHG Foundation] While ctDNA technologies build on the successes of analysing foetal DNA for non-invasive prenatal testing, and show clear promise for the treatment of cancer, the technology is still new, there are uncertainties about its clinical utility, and financial costs are unclear.
	4.13 Dép., diag. & prono. - Peau
Tool to Distinguish Moles from Melanoma [National Cancer Institute] The new tool is intended to help educate the public about the appearance and features of common moles (nevi), which pose no health risk, as well as those of atypical moles (dysplastic nevi), which can increase melanoma risk, and actual melanomas.
	4.2 Dép., diag. & prono. - Génome
From Bench To Blog - Making gene testing for cancer patients part of routine care [The Institute of Cancer Research] Our approach has already set a benchmark for access to gene testing. A number of NHS gene testing services have used our freely available resources to implement their own models, while AstraZeneca has begun an international study that is trialling our mainstream model in the USA, Spain and Italy.
	5. Traitements
Investigational drug abemaciclib shows promising activity against several cancer types [Dana-Farber Cancer Institute] “Because this study included 225 patients with different types of cancer, confirmatory clinical trials in specific patient populations are necessary to precisely define the role of abemaciclib in cancer care."
	5.10 Traitements - Essais
Cancer clinical trials to be streamlined to bring new treatments to UK patients sooner [Cancer Research UK] The Experimental Cancer Medicines Centre (ECMC) Collaboration Agreement will improve the network’s ability to carry out early phase clinical cancer trials, boosting research and development in the UK and bringing innovative new treatments to patients sooner.
France tightens rules in wake of fatal clinical trial [Science] France's Regional Health Agencies will be asked to carry out inspections at all clinical trial centers in the country, together with the National Agency for Medicines and Health Products Safety (ANSM). The latter agency will start producing monthly reports of all serious, unexpected side effects in phase I and II studies, and a new expert group at ANSM will review and approve each study, Touraine said.
	5.2 Pharma
Ipsen’s partner Exelixis announced results from randomized phase 2 trial CABOSUN that demonstrate that cabozantinib significantly improved progressionfree survival versus sunitinib in previously untreated advanced renal cell carcinoma [Ipsen] Ipsen in collaboration with Exelixis will share these results with European regulatory authorities and evaluate potential next steps in development and submission strategy for cabozantinib as a treatment of first-line advanced renal cell carcinoma.
Sandoz' biosimilar rituximab regulatory submission accepted by European Medicines Agency [Novartis] Sandoz believes that the totality of data in its submission will demonstrate that our biosimilar rituximab has essentially the same biological substance as, and the final drug product is highly similar to, the reference product.
	6. Lutte contre les cancers
Physician Communication Needed to Promote Informed Decision-Making for Patients with Advanced Cancer | Weill Cornell Newsroom [Weill Cornell Medical College] Delivering sensitive information to dying patients is difficult for many oncologists and many avoid such discussions. Indeed, 38 percent of the patients had never discussed their prognoses with their oncologist.
The one time WebMD didn’t tell me it was cancer, it was [STAT] It’s a running joke that no matter what symptoms you plug into WebMD, cancer is one of the possible diagnoses. So I was pleasantly surprised when cancer wasn’t high on the list in a search I did. But it should have been.
	6.1 Observation
Worry about wasting GP’s time stopping people from reporting cancer symptoms [Cancer Research UK] The study explored the reasons why some people are more likely to worry about wasting a GP’s time and delay reporting possible cancer symptoms.
'NHS treatment delay' caused cancer patient's death [BBC News] A man died from operable cancer after an NHS trust failed to act on advice from another hospital, an ombudsman's report has revealed.
	6.10 Politiques
Brexit 'could slow access to new medicines and delay cure for cancer' [The Telegraph] Pharmaceutical giants said a leave vote would come at “the worst possible time” in drug development, creating uncertainty which could disrupt major advances in the pipeline.
	6.6 Publications
ORCID identifiers now live in the Research Councils' grants system (Je-S) [Research Councils UK] Researchers can now create or connect their ORCID identifier (ORCID iD) in the Research Councils’ grants system (Je-S) by logging in to their personal information page. This is an important first step towards improving the flow of research information across the higher education sector.
	6.7.3 DMP
Patient can't always access complete medical records, doctors say [Reuters] In reality, the contents of electronic records may be limited by doctors’ concerns about disputes with patients about what the records say, fear of malpractice litigation, and questions about how much information to give certain individuals like minors and people with mental illness, these physicians argue.
	6.9 Controverses
Trouble at Santa Cruz Biotechnology [In the Pipeline] The commercial antibody market is already a mess, although that’s not a new development, but it’s gotten messier.